GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial infarction (MI) and percutaneous revascularization. However, the consequences of GLP-1R activation before ischemic myocardial injury remain unclear. RESEARCH DESIGN AND METHODS: We assessed the pathophysiology and outcome of coronary artery occlusion in normal and diabetic mice pretreated with the GLP-1R agonist liraglutide. RESULTS: Male C57BL/6 mice were treated twice daily for 7 days with liraglutide or saline followed by induction of MI. Survival was significantly higher in liraglutide-treated mice. Liraglutide reduced cardiac rupture (12 of 60 versus 46 of 60; P = 0.0001) and infarct size (21 ± 2% versus 29 ± 3%, P = 0.02) and improved cardiac output (12.4 ± 0.6 versus 9.7 ± 0.6 ml/min; P = 0.002). Liraglutide also modulated the expression and activity of cardioprotective genes in the mouse heart, including Akt, GSK3β, PPARβ-δ, Nrf-2, and HO-1. The effects of liraglutide on survival were independent of weight loss. Moreover, liraglutide conferred cardioprotection and survival advantages over metformin, despite equivalent glycemic control, in diabetic mice with experimental MI. The cardioprotective effects of liraglutide remained detectable 4 days after cessation of therapy and may be partly direct, because liraglutide increased cyclic AMP formation and reduced the extent of caspase-3 activation in cardiomyocytes in a GLP-1R–dependent manner in vitro. CONCLUSIONS: These findings demonstrate that GLP-1R activation engages prosurvival pathways in the normal and diabetic mouse heart, leading to improved outcomes and enhanced survival after MI in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These agents exert their anti-atherosclerotic effects through various mechanisms, including by improving blood lipid profiles,444 preserving endothelial integrity and regulating endothelial function,445 as well as modulating inflammatory processes.70”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [445]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 4×
“Glucagon-like peptide-1 (GLP-1), a member of the proglucagon-derived peptide family (2), exerts favorable actions on cardiovascular function in both preclinical and clinical studies.”
BackgroundInfluentialSelf-citationRegulation of cardiac hypertrophy by intracellular signalling pathways
Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,866 · cited 1×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 3×
“The GLP-1 metabolite, GLP-1, also exerts cardioprotective actions when administered postischemia (3,16), further highlighting the complexity of different GLP-1–related peptides on the ischemic heart.”
BackgroundSelf-citationJuhaszova, M., Zorov, D. B., Kim, S.-H., Pepe, S., Fu, Q., Fishbein, K. W., Ziman, B. D., Wang, S., Ytrehus, K., Antos, C. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19906 · Cited by 1,026
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 3×
“A pilot study of GLP-1 administration for 72 h in human subjects with left ventricular (LV) dysfunction after myocardial injury and angioplasty demonstrated reduced hospital stay and improved global and regional LV wall motion scores, benefits that remained detectable even several weeks after hospital discharge (14).”
BackgroundResultGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 2×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
ResultSelf-citationHeymans, S., Luttun, A., Nuyens, D., Theilmeier, G., Creemers, E., Moons, L., Dyspersin, G. D., Cleutjens, J. P. M., Shipley, M., Angellilo, A., et al. (1999) · Nature Medicine · doi:10.1038/13459 · Cited by 794 · cited 2×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
BackgroundSokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656 · cited 2×
“Similarly, a 5-week course of GLP-1 infusion improved parameters of LV function, functional status, and quality of life in both diabetic and nondiabetic subjects with congestive heart failure (15).”
BackgroundGlucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Self-citation
Cited by
Items 401–500 of 592
Gut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
Diabetes mellitus tipo 2: nuevos tratamientos
Ascaso, J. F. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.05.041 · Cited by 17
Wang, B., Ni, Y., ZHONG, J., & Sun, F. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00167.x · Cited by 11
Sadi, A. M., Afroze, T., Siraj, M. A., Momen, A., White-Dzuro, C. G., Khat, D. Z., Handa, S., Ban, K., Kabir, M. G., Trivieri, M. G., et al. (2018) · Clinical Science · doi:10.1042/cs20171337 · Cited by 11
Self-citationCox, E. J., Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2020) · US Endocrinology · doi:10.17925/use.2020.16.2.80 · Cited by 10
Notomi, Y., Isomura, T., Kanai, S., Maeda, M., Hoshino, J., Kondo, T., Fukada, Y., & Furukawa, K. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.04.006 · Cited by 9
Incretin-Related Drug Therapy in Heart Failure
Vest, A. R. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0232-6 · Cited by 10
Kyohara, M., Shirakawa, J., Okuyama, T., Kimura, A., Togashi, Y., Tajima, K., Hirano, H., & Terauchi, Y. (2017) · Endocrinology · doi:10.1210/en.2017-00339 · Cited by 9
Mubarak, H. A., Mahmoud, M. F., Shoukry, H. S., Merzeban, D. H., Sayed, S., & Rashed, L. A. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12956 · Cited by 9
Blood Glucose Control and Coronary Heart Disease
Bianchi, C., Penno, G., Miccoli, R., & Prato, S. D. (2010) · Herz · doi:10.1007/s00059-010-3340-4 · Cited by 9
“Preclinical data have shown that GLP-1 receptor agonist such as exenatide and liraglutide may reduce postischemic infarct size and improve left ventricular function after transient coronary artery occlusion in animal models [78, 79 ].”
BackgroundThomas, R., Lim, S. Y., Qiang, B., Osherov, A. B., Ghugre, N. R., Noyan, H., Qi, X., Wolff, R., Ladouceur-Wodzak, M., Berk, T. A., et al. (2015) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-015-0197-y · Cited by 9
“The activation (phosphorylation) of Akt has been shown to be associated with myocyte survival and reduction in infarct size in a number of pre-clinical studies [33–35].”
BackgroundSelf-citationNeto, S. R. M., Castiglione, R. C., Pontes, A., de Oliveira, D. F., Ferraz, E. B., Nascimento, J. H. M., & Bouskela, E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148402 · Cited by 9
“The underlying mechanisms of incretins are not well defined, but it may involve AMPK since administration of AMPK antagonist (compound C) reversed the beneficial effects of incretin-based therapies [20].”
BackgroundPéptido similar al glucagón tipo 1 y supervivencia de la célula cardiaca
Ravassa, S., Zudaire, A., & Díez, J. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.07.007 · Cited by 13
Wang, C., Yu, H., Wei, L., Zhang, J., Hong, M., Chen, L., Dong, X., & Fu, L. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29639 · Cited by 9
Deciphering ventricular GLP-1 action: time for a change of heart
Ussher, J. R. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00680.2014 · Cited by 9
“Moreover, a 1-wk pretreatment with liraglutide improved left ventricular (LV) function and reduced adverse LV remodeling in both nondiabetic and diabetic mice (14), whereas a 3-mo infusion of GLP-1(7-36) improved LV function and improved survival in the spontaneously hypertensive and heart failure-prone rat (15).”
BackgroundPicatoste, B., RamÃrez, E., Caro‐Vadillo, A., Iborra, C., Egido, J., n, J. T., & Lorenzo, Ó. (2013) · PLoS ONE · doi:10.1371/annotation/df98874f-c1bd-4a13-b474-942fbb956287 · Cited by 9
Akçılar, R., Taşar, M., Kar, F., Arı, N. S., Saygılı, S. K., Koçak, F. E., & Koçak, C. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123896 · Cited by 8
Zhang, J., Lei, Y., Li, R., He, Y., & Chen, Z. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10678-z · Cited by 8
“Similarly, as a novel class of antihyperglycemic agents, extensive research has demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RAs) can alleviate myocardial fibrosis through multiple mechanisms [148, 149].”
Mechanisms of neuroprotective action of incretin mimetics
Vlasov, T. D., Симаненкова, А. В., Владимировна, Д. С., & Shlyakhto, E. V. (2016) · Diabetes Mellitus · doi:10.14341/dm7192 · Cited by 8
Mechanism of and strategy to mitigate liraglutide-mediated positive chronotropy
Jøns, C., Porta‐Sánchez, A., Lai, P. F. H., Wauchop, M., Massé, S., Azam, M. A., Asta, J. A., Rose, R. A., & Nanthakumar, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119815 · Cited by 8
Glucagon-like peptide 1 and cardiac cell survival
Ravassa, S., Zudaire, A., & Díez, J. (2012) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.11.004 · Cited by 11
Dipeptidyl peptidase-IV in chronic heart failure with reduced ejection fraction
Lourenço, P., Silva, S., Cunha, F. M., Pereira, J. C., Ribeiro, A., Silva, N., Guimarães, J. T., Araújo, J. P., & Bettencourt, P. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.042 · Cited by 8
Anti-inflammatory effects of GLP1-RA drugs
Quintana, L., Tabaza, N., Kurt, B., & Kahles, F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag218 · Cited by 7
The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease
Guo, Z. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00609-1 · Cited by 8
“…et al. found that liraglutide had a cardioprotective and survival advantage over metformin in a diabetic mouse model with myocardial infarction despite comparable glycemic control, which is partially due to the increased cAMP formation mediated by liraglutide in a GLP-1R-dependent manner [89].”
Aydos, D., Aksoy, Z. B., Ünal, M. A., Akçalı, K. C., Bitirim, C. V., & Turan, B. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02828-z · Cited by 7
“Above and beyond the glucose-lowering and weight-lowering effects of GLP-1 mimetics, recent evidence highlighted their cardioprotective actions in addition to activation of cytoprotective pathways in pancreatic β-cells [14–16].”
Pan, X., Li, C., & Gao, H. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.648399 · Cited by 7
“Being one of the class B G-protein-coupled receptor family, GLP-1R exerts its physiological function mainly through two pathways: GPCR dependent pathway and GPCR-independent pathway (Noyan-Ashraf et al., 2009).”
BackgroundRepurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation
Wasim, R., Ansari, T. M., Siddiqui, M. H., Ahsan, F., Shamim, A., Singh, A. N., Shariq, M., Anwar, A., Siddiqui, A. R., & Parveen, S. (2023) · Hormone and Metabolic Research · doi:10.1055/a-1971-6965 · Cited by 7
Tudurachi, B.-S., Anghel, L., Tudurachi, A., Sascău, R. A., Zanfirescu, R.-L., & Stătescu, C. (2024) · Biomedicines · doi:10.3390/biomedicines12061314 · Cited by 7
“In mouse cardiomyocytes cultivated in vitro, it also raises cAMP and lowers apoptosis [175].”
Schneider, C. A., Pfister, R., & Erdmann, E. (2010) · Herz · doi:10.1007/s00059-010-3337-z · Cited by 7
“des Schweins die Infarktgröße signifikant [56, 57].”
Psallas, M., & Manes, C. (2012) · Europe PMC (PubMed Central) · Cited by 6
Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction
Li, J., Chen, Y., Chen, W.-R., You, Q., Li, B., Zhou, H., Zhang, Y., & Han, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0553-3 · Cited by 7
“GLP-1 improved outcomes after experimentally-induced myocardial infarction [36].”
BackgroundBacha, Z., Javed, J., Sheraz, M., Sikandar, M., Zakir, M., Ali, M. A., Khan, M., Iqbal, A., Rehman, A., Alam, U., et al. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001057 · Cited by 6
Role of endogenous incretin hormones, GLP-1 and GIP, in cardiovascular physiology
Trivedi, K., & Dolinsky, V. W. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0163 · Cited by 7
Therapeutic Repurposing of Antidiabetic Drugs in Diabetes-associated Comorbidities
Pathak, K., Pathak, M. P., Saikia, R., Gogoi, U., Das, R. J., Patowary, P., Kaishap, P. P., Bordoloi, S., Das, J., Sarma, H., et al. (2023) · Current Drug Therapy · doi:10.2174/1574885518666230516150404 · Cited by 8
Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
Freeman, J. S. (2012) · PubMed · Cited by 6
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
Beyond glucose: cardiovascular effects of incretins and dipeptidyl peptidase-4 substrates
Shannon, R. P., & Angeli, F. S. (2012) · European Heart Journal Supplements · doi:10.1093/eurheartj/sus001 · Cited by 6
“Genetic knockout of DPP-4 or inactivation by diprotin A prevents N-terminal cleavage of SDF-1a and provides an increased pool of intact chemokine (SDF-1a [1–68]) for efficient homing to sites of myocardial injury, via interaction with the CXCR-4 homing receptor.”
BackgroundYang, X., & Liang, Z. (2018) · Herz · doi:10.1007/s00059-018-4748-5 · Cited by 6
“Liraglutide, a glucagon-like peptide-1 analog, has shown the potential in reducing infarct size and improving cardiac output in normal and diabetic mice [10].”
BackgroundCosentino, N., Bonomi, A., Campodonico, J., Veglia, F., Ferrari, G. M. D., Genovese, S., & Marenzi, G. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.02.003 · Cited by 6
Mather, K. J., Considine, R. V., Hamilton, L., Patel, N. A., Mathias, C. J., Territo, W. L., Goodwill, A. G., Tune, J. D., Green, M. A., & Hutchins, G. D. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00712 · Cited by 6
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Μatsumoto, T., Yagi, T., & Okada, M. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005364 · Cited by 5
Setji, T. L., & Feinglos, M. N. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.13.2 · Cited by 5
Impact of Systemic Dipeptidyl Peptidase-4 Inhibitor Use in Diabetic Macular Edema
Rahimy, E., Baker, K., Thompson, D. E., Saroj, N., & On behalf of the VIVID and VISTA Study Investigators (2020) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20200326-04 · Cited by 5
Myat, A., Redwood, S. R., Arri, S. S., Gersh, B. J., Bhatt, D. L., & Marber, M. S. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00635-6 · Cited by 5
Demkes, E. J., Wenker, S., Silvis, M. J. M., van Nieuwburg, M. M. J., Visser, M., Jansen, M. S., Brans, M. A. D., Velema, E., Sluijter, J. P. G., Hoefer, I. E., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.702326 · Cited by 5
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 4
Cardiometabolic interventions – focus on transcriptional regulators
Chai, J. T., & Choudhury, R. P. (2013) · European Journal of Cardiovascular Medicine · doi:10.5083/ejcm.20424884.102 · Cited by 4
Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies
Stranges, P. M., & Khanderia, U. (2012) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098612454290 · Cited by 5
“Various theories have been proposed, including improved glucose utilization during ischemia, as well as direct action at cardiac GLP-1 receptors resulting in improved cardiac contractility and expression of cardioprotective proteins [Noyan-Ashraf et al. 2009].”
BackgroundThe Influence of Liraglutide for Heart Failure: A Meta-Analysis of Randomized Controlled Trials
Zhang, Y., Chen, Q., Huang, G., & Wang, L. (2019) · The Heart Surgery Forum · doi:10.1532/hsf.2513 · Cited by 4
May, A. T., Wang, H., Mahavadi, S., Grider, J. R., & Murthy, K. S. (2017) · The FASEB Journal · doi:10.1096/fasebj.31.1_supplement.888.5 · Cited by 4
Myat, A., Arri, S. S., Bhatt, D. L., Gersh, B. J., Redwood, S. R., & Marber, M. S. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0193-4 · Cited by 4
“It is this expression of the GLP-1R in the myocardium, and the overall ubiquity of the receptor, that has fuelled growing interest in the direct and indirect cardiovascular (CV) effects of native GLP-1 [24,25], its degradation product GLP-1(9-36) [26,27], and the degradation-resistant GLP-1R agonists [28-30].”
BackgroundPotential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists
Chilton, R. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000483 · Cited by 4
“Numerous preclinical investigations of the effects of GLP-1 in animal models of MI have provided evidence of improvements in infarct size and cardiac function [27-33], with no deleterious histopathological effects on the pancreas [34-36].”
BackgroundKonservative Therapie der Adipositas
Meyhöfer, S., Steffen, A., Kalscheuer, H., Wilms, B., & Schmid, S. M. (2018) · Somnologie - Schlafforschung und Schlafmedizin · doi:10.1007/s11818-018-0159-3 · Cited by 4
“In Mausversuchen ließen sich durchGLP-1eineNeubildungvonβ-Zellen im endokrinen Pankreas [4], eine Risikoreduktion von Herz-KreislaufErkrankungen sowie zentral eine Suppression der Nahrungsaufnahme nachweisen [26].”
BackgroundCardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?
Liu, Y., Kubota, S., Iizuka, K., & Yabe, D. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13302 · Cited by 5
“blocked by exendin(9-39), yet were preserved in GLP-1R-deficient cardiomyocytes(12), suggesting that GLP-1(9-36a) or its metabolite interacts with a yet-to-beidentified receptor different from GLP1R to exert cardioprotective effects.”
BackgroundBriand, F., Brousseau, E., Maupoint, J., Dubroca, C., Costard, C., Breyner, N. M., Burcelin, R., & Sulpice, T. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173316 · Cited by 4
Zhong, Z., Chen, K., Zhao, Y., & Xia, S. (2021) · International Journal of Endocrinology · doi:10.1155/2021/9993229 · Cited by 5
Afrăsânie, I., Matei, I. T., Leancă, S. A., Chetran, A., Costache, A. D., Afrăsânie, V.-A., Dmour, B.-A., Crișu, D., Bădescu, M. C., Șerban, L., et al. (2023) · Life · doi:10.3390/life13020443 · Cited by 5
Potential Role of GLP-1 Based Therapeutics in Coronary Artery Disease
Xiong, Q., Wang, J., Huang, K., Li, W., & Zhang, L. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2811315 · Cited by 4
“[28, 42,44,45,47,48,50–59]).”
The Influence of Incretin Mimetics on Cardiovascular Risk Factors in Diabetes
Kinalska, I., Bednarska-Chabowska, D., Adamiec-Mroczek, J., & Hak, Ł. (2012) · ISRN Endocrinology · doi:10.5402/2012/625809 · Cited by 4
“[29] confirmed cardioprotective prosperities of liraglutide in animal model.”
BackgroundNew Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease
Almutairi, M. G., Chan, J. S. F., & Ussher, J. R. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.904626 · Cited by 3
“B-cell lymphoma 2 [Bcl2], Bcl-2 associated death promoter) often reflect decreased apoptosis (Bose et al., 2005; Noyan-Ashraf et al., 2009; Timmers et al., 2009; Bao et al., 2011).”
BackgroundMethodInfluentialMahmoud, A., Sheashaa, H., Killian, M., Awad, K., Ibrahim, R., Mahmoud, A., Farina, J., Abdelnabi, M., Kamel, I., Horn, B., et al. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134588 · Cited by 3
Zhou, Y., Huang, S.-T., CHENG-WU, L., Qiao, Y., Liu, Q., Chen, T., Wang, J., & Liu, Y. (2022) · Advanced Biology · doi:10.1002/adbi.202200130 · Cited by 4
Self-citationGut-Derived Hormones—Cardiac Effects of Ghrelin and Glucagon-Like Peptide-1
Ruozi, G., Bortolotti, F., & Recchia, F. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803111-7.00006-3 · Cited by 5
Симаненкова, А. В., Макарова, М. Н., Васильевна, В. Л., Butomo, M. I., Владимировна, Д. С., & Shlyakhto, E. V. (2018) · Regional blood circulation and microcirculation · doi:10.24884/1682-6655-2018-17-2-57-63 · Cited by 3
Nabrdalik, K., Tomasik, A. R., Irlik, K., Hendel, M., Kwiendacz, H., Radzik, E., Pigoń, K., Młyńczak, T., Gumprecht, J., Nowalany-Kozielska, E., et al. (2023) · Scientific Reports · doi:10.1038/s41598-022-24855-6 · Cited by 3
Liraglutide Suppresses Myocardial Fibrosis Progression by Inhibiting the Smad Signaling Pathway
Sun, W., Mi, H., He, D.-Y., Li, W., & Songyang, Y. (2023) · Current Medical Science · doi:10.1007/s11596-023-2776-8 · Cited by 3
Beneficial and Detrimental Effects of Glycemic Control on Cardiovascular Disease in Type 2 Diabetes
Taub, P. R., Higginbotham, E., & Henry, R. R. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0332-4 · Cited by 3
“Additionally, a number of animal studies have demonstrated cardioprotective effects of GLP-1 through infarct size minimization and recovery enhancement [56–59].”
BackgroundLiraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes
Hribal, M. L., & Sesti, G. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.20 · Cited by 3
shalaby, A. (2014) · Journal of Pharmaceutical Research International · doi:10.9734/bjpr/2014/9297 · Cited by 4
T1R3: how to indulge the gut's sweet tooth
Iakoubov, R., & Lauffer, L. M. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00418.2012 · Cited by 3
Lu, X., Harada, N., Yasuda, T., Ikeguchi, E., Kobayashi, D., Denda, M., Seno, Y., Yamane, S., Yabe, D., Otaka, A., et al. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0026 · Cited by 2
Theodorakis, N., Kreouzi, M., & Nikolaou, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10506-1 · Cited by 3
“This suggests that GLP-1RAs may offer cardioprotection and improve outcomes following ischemic cardiac injury [22].”
Repetti, G. G., Abel, E. D., Tontonoz, P., & Sallam, T. (2026) · Circulation Research · doi:10.1161/circresaha.126.328680 · Cited by 3
Molecular and clinical roles of incretin-based drugs in patients with heart failure
Orabi, B., Kaddoura, R., Omar, A. S., Carr, C. S., & Alkhulaifi, A. M. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9702-3 · Cited by 2
Zhang, J., Chen, Y., Wang, J., Xia, H., & Zheng, Y. (2021) · PubMed · doi:10.18999/nagjms.83.2.343 · Cited by 2
Liraglutide innovations: a comprehensive review of patents (2014–2024)
Pandey, A. K., & Goyal, A. K. (2024) · Pharmaceutical Patent Analyst · doi:10.1080/20468954.2024.2366693 · Cited by 3
Naoum, I., Saliba, W. I., Barnett‐Griness, O., Aker, A., & Zafrir, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185541 · Cited by 3
Lesven, S., Gautier, J. F., & Maréchaud, R. (2010) · Annales d Endocrinologie · doi:10.1016/j.ando.2010.09.001 · Cited by 2
Liraglutide, a GLP‐1 Analogue to Treat Diabetes
Knudsen, L. B. (2010) · Wiley eBooks · doi:10.1002/9783527630035.ch14 · Cited by 2
Pleiotropic Effects of GLP-1. Cardiovascular Evidence of Effectiveness
Alarcón, P. P., Cascales, A. B. H., Ruiz, A. L., Gil, M. Á. I., Torres, A. H., & Gil, M. D. H. (2013) · Pharmacology & Pharmacy · doi:10.4236/pp.2013.49091 · Cited by 2
“That has been regarded as a cardioprotective effect of the myocardium with consequent smaller necrosis [32] zone.”
BackgroundLalic, N. M., & Landers, B. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0165 · Cited by 2
Glucagon-like peptide-1 e sistema cardiovascolare: meccanismi fisiopatologici
Avogaro, A. (2010) · Giornale italiano di cardiologia · doi:10.1714/565.6706 · Cited by 2
Pan, X., Xu, Q., Chen, J., Wang, T., Zhang, M., Wang, H., & Gao, H. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10432 · Cited by 3
Incretin peptides: new targets in correction of ischemic-reperfusion myocardial damages
Tarasova, A. P., Pokrovsky, M. V., & Даниленко, Л. М. (2020) · Человек и его здоровье · doi:10.21626/vestnik/2020-1/04 · Cited by 2
“чтобы потенцировать индуцированное глюкозой закрытие KАТФ-зависимых чувствительных каналов, тем самым создавая клеточную деполяризацию через Ca-зависимые каналы и приток Ca, который вводит в действие экзоцитоз инсулина [24].”
Abood, A., Awad, H., & Hassan, S. M. (2021) · Ain Shams Medical Journal · doi:10.21608/asmj.2021.167313 · Cited by 3
“In fact, GLP-1R agonists have direct beneficial effects on the heart such as improving left ventricular performance after myocardial infarction (15) .”
BackgroundFULMINANT MYOCARDITIS-A UNIQUE COMPLICATION OF COVID-19
Ahmed, A., Young, S. K., & Lantz, R. H. (2021) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(21)03378-7 · Cited by 2
Kahal, H. (2013) · Repository@Hull (Worktribe) (University of Hull) · Cited by 2
Vijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1423962 · Cited by 1
Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction
Li, Q., Wu, C., Sun, S., Yang, L.-C., Li, Y., Niu, Y., Zhang, L., Li, W., & Yu, Y. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13517 · Cited by 1
Alicic, R. Z., & Neumiller, J. J. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.003 · Cited by 1
Yang, Y., Dou, J., & Wu, Y. (2025) · Medicine · doi:10.1097/md.0000000000042707 · Cited by 1
“[14]”
Avogaro, A. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70184 · Cited by 2
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040447 · Cited by 1
“As might be expected from these biochemical data, liraglutide (30 nM) alone failed to change left intraventricular pressure in isolated perfused adult mice hearts [108].”
Kim, Y., Lee, E. Y., & On behalf of the Korean Diabetic Kidney Disease Study Group (2026) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.26.272 · Cited by 1
“Preclinical studies suggest that GLP-1 RAs improve endothelial function and exert anti-inflammatory and antioxidative effects in vascular and cardiac tissues, partly via modulation of NF-κ B signaling and enhancement of nitric oxide bioavailability [28].”
Ahluwalia, R., & Vora, J. P. (2012) · The British Journal of Diabetes · doi:10.1177/1474651411431846 · Cited by 1
Effects of alogliptin benzoate in hemodialysis patients with diabetes
Nakamura, Y., Simizu, T., Fujita, K., Inoue, M., Gotoh, H., Goto, Y., Inagaki, M., & Oguchi, K. (2011) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.45.49 · Cited by 1
Toyooka, N., Adachi, I., Minehira, D., Takeda, D., Miyawaki, S., Kato, A., Miyazaki, A., Miyatake, R., Umezaki, M., Miura, K., et al. (2014) · Heterocycles · doi:10.3987/com-14-s(k)29 · Cited by 1
Kardiovaskuläre Effekte inkretinbasierter Therapien
Lehrke, M., & Marx, N. (2012) · Herz · doi:10.1007/s00059-012-3599-8 · Cited by 1
First GLP-1 analog liraglutide: the result of clinical trails on efficacy
As, A., & Kamynina, L. L. (2011) · Diabetes Mellitus · doi:10.14341/2072-0351-5815 · Cited by 1
The Incretin System and Cardiovascular Risk: Effects of Incretin-Targeted Therapies
Mundil, D., Noyan-Ashraf, M. H., & Husain, M. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0141-5 · Cited by 1
Self-citation
Metadata
- Authors
- Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J.
- Affiliations
- Toronto General Hospital (CA)
- University of Toronto (CA)
- Mouse Imaging Centre, Department of Medical Biophysics, Hospital for Sick Children, Toronto, Ontario, Canada;
- Hospital for Sick Children (CA)
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-01-16
- Volume
- 58
- Issue
- 4
- Pages
- 975-983
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2661586
- OpenAlex
- W2150913805
- Cited by
- 575
- References
- 47
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 26 · 2023: 20 · 2022: 21 · 2021: 28 · 2020: 25 · 2019: 25 · 2018: 32 · 2017: 36 · 2016: 33 · 2015: 49 · 2014: 41 · 2013: 47 · 2012: 53
- FWCI
- 35.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (80668)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- liraglutide, GLP-1 receptor agonists, myocardial infarction, cardioprotection, diabetic cardiomyopathy, cardiac rupture, infarct size, Akt/GSK-3β signaling, PPARδ, metformin, caspase-3, cyclic AMP
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Disease Models, Animal, Heart, Cardiomegaly, Humans, Male, Mice, Inbred C57BL, Myocardial Infarction, Organ Size, Receptors, Glucagon, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.